GUILLERMO
LÓPEZ VIVANCO
Ikertzailea 2022-(e)ra arte
University Medical Center Hamburg-Eppendorf
Hamburgo, AlemaniaUniversity Medical Center Hamburg-Eppendorf-ko ikertzaileekin lankidetzan egindako argitalpenak (2)
2013
-
Preference for subcutaneous or intravenous administration of trastuzumab in patients with HER2-positive early breast cancer (PrefHer): An open-label randomised study
The Lancet Oncology, Vol. 14, Núm. 10, pp. 962-970
2012
-
Docetaxel combined with irinotecan or 5-fluorouracil in patients with advanced oesophago-gastric cancer: A randomised phase II study
British Journal of Cancer, Vol. 107, Núm. 3, pp. 435-441